Trial
NCT03234153
Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
AstraZeneca
Condition
Muscle-invasive Bladder Cancer
Intervention
Durvalumab (Imfinzi)
Why stopped
low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-17